Advances in Cancer Research
Herausgegeben:Fisher, Paul B.; Tew, Kenneth D.
Advances in Cancer Research
Herausgegeben:Fisher, Paul B.; Tew, Kenneth D.
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Advances in Cancer Research, Volume 142, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.
Andere Kunden interessierten sich auch für
- Advances in Cancer Research89,99 €
- Advances in Cancer Research110,99 €
- Advances in Cancer Research94,99 €
- Advances in Clinical Chemistry108,99 €
- Cancer and Development124,99 €
- Cytokine Effector Functions in Tissues94,99 €
- Advances in the Neurochemistry and Neuropharmacology of Tourette Syndrome117,99 €
-
-
-
Advances in Cancer Research, Volume 142, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.
Produktdetails
- Produktdetails
- Advances in Cancer Research Volume 142
- Verlag: Academic Press / Elsevier Science & Technology
- Artikelnr. des Verlages: S0065-230X(19)X0003-2
- Englisch
- Abmessung: 13mm x 152mm x 229mm
- Gewicht: 480g
- ISBN-13: 9780128171530
- Artikelnr.: 53610526
- Advances in Cancer Research Volume 142
- Verlag: Academic Press / Elsevier Science & Technology
- Artikelnr. des Verlages: S0065-230X(19)X0003-2
- Englisch
- Abmessung: 13mm x 152mm x 229mm
- Gewicht: 480g
- ISBN-13: 9780128171530
- Artikelnr.: 53610526
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based compan
y (at Johns Hopkins Medical Center) focusing on imaging and therapy ("theranostics?) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
y (at Johns Hopkins Medical Center) focusing on imaging and therapy ("theranostics?) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
1. Highly variant DNA methylation in normal tissues identifies a distinct subclass of cancer patientsJayashri Ghosh, Bryant Schultz, Christos Coutifaris and Carmen Sapienza2. Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylationsRyan M. Phillips, Christine Lam, Hailun Wang and Phuoc T. Tran3. The second genome: Effects of the mitochondrial genome on cancer progressionAdam D. Scheid, Thomas C. Beadnell and Danny R. Welch4. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumorsManny D. Bacolod, Francis Barany, Karsten Pilones, Paul B. Fisher and Romulo J. de Castro5. HVEM network signaling in cancerJohn R. Sedý and Parham Ramezani-Rad6. Pharmacology of ME-344, a novel cytotoxic isoflavoneLeilei Zhang, Jie Zhang, Zhiwei Ye, Danyelle M. Townsend and Kenneth D. Tew
1. Highly variant DNA methylation in normal tissues identifies a distinct subclass of cancer patientsJayashri Ghosh, Bryant Schultz, Christos Coutifaris and Carmen Sapienza2. Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylationsRyan M. Phillips, Christine Lam, Hailun Wang and Phuoc T. Tran3. The second genome: Effects of the mitochondrial genome on cancer progressionAdam D. Scheid, Thomas C. Beadnell and Danny R. Welch4. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumorsManny D. Bacolod, Francis Barany, Karsten Pilones, Paul B. Fisher and Romulo J. de Castro5. HVEM network signaling in cancerJohn R. Sedý and Parham Ramezani-Rad6. Pharmacology of ME-344, a novel cytotoxic isoflavoneLeilei Zhang, Jie Zhang, Zhiwei Ye, Danyelle M. Townsend and Kenneth D. Tew